Terms: = Breast cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
2873 results:
1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
2. Anxiety Levels in Brazilian Women with Metastatic breast cancer Undergoing Palliative Chemotherapy: A Prospective Study.
Marcondes L; Silva LDS; Ribeiro CO; Oshiro NN; Nogueira LA; Guimaraes PRB; Kalinke LP
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1135-1141. PubMed ID: 38679972
[TBL] [Abstract] [Full Text] [Related]
3. Real-World treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
4. Dosimetric feasibility study ("proof of concept") of refractory ventricular tachycardia radioablation using proton minibeams.
Loap P; Giorgi M; Vu-Bezin J; Kirov K; Sampai JM; Prezado Y; Kirova Y
Cancer Radiother; 2024 Apr; 28(2):195-201. PubMed ID: 38599941
[TBL] [Abstract] [Full Text] [Related]
5. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A; Louis FM; van Ramshorst MS; Kessels R; Mandjes IA; Kemper I; Agterof MJ; van der Steeg WA; Heijns JB; van Bekkum ML; Siemerink EJ; Kuijer PM; Scholten A; Wesseling J; Vrancken Peeters MTFD; Mann RM; Sonke GS;
Lancet Oncol; 2024 May; 25(5):603-613. PubMed ID: 38588682
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
Peng DM; Li J; Qiu JX; Zhao L
World J Surg Oncol; 2024 Apr; 22(1):88. PubMed ID: 38582875
[TBL] [Abstract] [Full Text] [Related]
7. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
Lin D; Sturgeon KM; Muscat JE; Zhou S; Hobkirk AL; O'Brien KM; Sandler DP; Thompson CL
Breast Cancer; 2024 May; 31(3):519-528. PubMed ID: 38564089
[TBL] [Abstract] [Full Text] [Related]
8. Tumor-Infiltrating Lymphocytes in Triple-Negative breast cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract] [Full Text] [Related]
9. Alternative Lymphatic Drainage Pathways in the Trunk Following Oncologic Therapy.
Mehta M; Sarrami S; Moroni E; Fishman J; De La Cruz C
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S258-S261. PubMed ID: 38556685
[TBL] [Abstract] [Full Text] [Related]
10. Disparities in breast Reconstruction: An Analysis of treatment Choices.
Eregha N; Villalvazo Y; De La Cruz C
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S223-S227. PubMed ID: 38556678
[TBL] [Abstract] [Full Text] [Related]
11. Design and Development of Gold/reduced Graphene Oxide Nanocomposite loaded with Cyclophosphamide: Potential Application in treatment of breast cancer.
Hassan Mallah S; Abbas Jabir F; Abdulwahab Al-Askeri M
Asian Pac J Cancer Prev; 2024 Mar; 25(3):1007-1016. PubMed ID: 38546083
[TBL] [Abstract] [Full Text] [Related]
12. Surgical Resection of Primary Tumor for Bone Metastatic breast cancer Patients at Initial Presentation.
Kitsuya N; Matsuoka M; Onodera T; Yokota I; Iwasaki K; Suzuki Y; Hamasaki M; Kondo E; Iwasaki N
Anticancer Res; 2024 Apr; 44(4):1591-1601. PubMed ID: 38537990
[TBL] [Abstract] [Full Text] [Related]
13. Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage breast Carcinoma in Ireland.
McSorley LM; Tharmabala M; Al Rahbi F; Keane F; Evoy D; Geraghty JG; Rothwell J; McCartan DP; Greally M; O'Connor M; O'Mahony D; Keane M; Kennedy MJ; O'Reilly S; Millen SJ; Crown JP; Kelly CM; Prichard RS; Quinn CM; Walshe JM
Curr Oncol; 2024 Mar; 31(3):1302-1310. PubMed ID: 38534931
[No Abstract] [Full Text] [Related]
14. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
15. cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study.
Kashyap D; Bhattacharya S; Irinike S; Khare S; Das A; Singh G; Bal A
Breast Dis; 2024; 43(1):25-36. PubMed ID: 38517765
[TBL] [Abstract] [Full Text] [Related]
16. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in breast cancer.
Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
[TBL] [Abstract] [Full Text] [Related]
17. Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
Vo K; Ladbury C; Yoon S; Bazan J; Glaser S; Amini A
Breast Cancer; 2024 May; 31(3):485-495. PubMed ID: 38507145
[TBL] [Abstract] [Full Text] [Related]
18. Genome-wide analyses reveal the regulatory roles of DNA methylation-regulated alternative promoter transcripts in breast cancer.
Song Y; Shen T; Sun H; Wang X
Hum Genet; 2024 Mar; 143(3):385-399. PubMed ID: 38502355
[TBL] [Abstract] [Full Text] [Related]
19. Artificial Intelligence-Based Radiotherapy Contouring and Planning to Improve Global Access to cancer Care.
Court LE; Aggarwal A; Jhingran A; Naidoo K; Netherton T; Olanrewaju A; Peterson C; Parkes J; Simonds H; Trauernicht C; Zhang L; Beadle BM;
JCO Glob Oncol; 2024 Mar; 10():e2300376. PubMed ID: 38484191
[TBL] [Abstract] [Full Text] [Related]
20. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
[TBL] [Abstract] [Full Text] [Related]
[Next]
